A PROSPECTIVE OBSERVATIONAL STUDY ON SAFETY AND EFFICACY OF METFORMIN IN COMBINATION WITH DPP4 INHIBITORS IN TYPE 2 DIABETES MELLITUS

Abhinaya M; Swetha P; Chandana K; Akhila P; Manjula B

doi:10.38022/ajhp.v6i2.145

M. Abhinaya Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Gunthapally, Hyderabad, Telangana, India.
editor@ajhp.online
P. Swetha Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Gunthapally, Hyderabad, Telangana, India.
K. Chandana Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Gunthapally, Hyderabad, Telangana, India.
P. Akhila Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Gunthapally, Hyderabad, Telangana, India.
B. Manjula Department of Pharmaceutics, Avanthi Institute of Pharmaceutical Sciences, Gunthapally, Hyderabad, Telangana, India.

DOI https://doi.org/10.38022/ajhp.v6i2.145

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to persistent hyperglycemia and various complications. Effective glycemic control is essential to prevent disease progression and associated complications. Metformin is widely used as a first-line antidiabetic agent, while DPP-4 inhibitors such as Sitagliptin improve glycemic control by enhancing incretin hormone activity. The present prospective observational study was conducted to evaluate the safety and efficacy of metformin in combination with DPP-4 inhibitors in patients with T2DM. A total of 80 patients were enrolled and observed over a period of six months. Patient demographics, family history, BMI, comorbidities, prescription patterns, and adverse drug reactions were recorded. Efficacy was assessed by comparing fasting plasma glucose (FPG) and random blood sugar (RBS) levels before and after treatment. The results demonstrated a significant reduction in FPG from 170.8 mg/dL to 120.6 mg/dL, indicating improved glycemic control. RBS levels also showed notable improvement following therapy. Safety evaluation revealed that only 5% of patients experienced mild adverse effects, with no serious complications reported. The study concludes that metformin in combination with DPP-4 inhibitors is an effective and well-tolerated therapeutic approach for managing T2DM, offering better glycemic control and improved patient outcomes in routine clinical practice.

Keywords: Type 2 Diabetes Mellitus, Metformin, DPP-4 Inhibitors, Glycemic Control, Safety, Efficacy, Hyperglycemia

Downloads

Download data is not yet available.

References

1. American Diabetes Association. Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S350.
2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
3. Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21(3):115-117.
4. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585.
5. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011;13(1):7-18.
6. Drucker DJ. Incretin-based therapy and type 2 diabetes. Cell Metab. 2006;3(3):153-165.
7. Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;10:389.
8. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes. Diabetes Metab. 2010;36(6):S33-S41.
9. Pulusu VS, Chilamula S, Holkunde A, Gunturi R, Vidiyala P, Bashetty SR. Microplastics and nanoplastics: Environmental pathways, ecological impacts, and regulatory perspectives. Open Access Library Journal. 2025;12(12):1-31.
10. Nauck MA, Meier JJ. Incretin therapies: highlighting common features and differences. Diabetes Obes Metab. 2019;21(S1):21-36.
11. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in T2DM. Diabetes Care. 2018;41(12):2669-2701.
12. Pulusu VS, Chilamula S, Holkunde A, Gunturi R, Vidiyala P, Anekalla TR. Microplastics in the Environment: Sources, Detection Techniques, and Analytical Challenges. Open Access Libr. J. 2025;12:1-33.
13. R. Prasad P. L., S. Govindaraj, P, Jahnavi, P. Popatrao Taru, T. Tummala, P. Vidiyala, N. Vidiyala, P. Balaji .Metal Oxide Functionalized Nanoparticles for the Treatment of Bacterial Infection: Synthesis,Characterization, and Therapeutic Applications. J. Appl. Organomet. Chem., 2025, 5(3), 232-257.
14. Velmurugan R, Ravikumar L, Teriveedhi VK, Vidiyala P, Jahnavi P, Vodeti R, Elumalai S. Optimized Idronoxil-Loaded Polycaprolactone Nanoparticles for Targeted Liver Cancer Therapy: A Novel Approach in Drug Delivery Systems.
15. Holman N, Young B, Gadsby R. Current prevalence of Type 2 diabetes and its complications. Diabet Med. 2015;32(9):1119-1127.
16. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in Type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015;38(1):140-149.
17. Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(10): 859-867.
18. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of DPP-4 inhibitors in Type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696-708.
19. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112-120.